How have RZLT and SPRY total returns compared?

Over the past 5 years, RZLT delivered -9.57% and SPRY delivered -16.35% annualized total return. Past performance doesn't predict future results.

Rezolute, Inc. (RZLT) vs ARS Pharmaceuticals, Inc. (SPRY)

A side-by-side comparison of Rezolute, Inc. and ARS Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

RZLT

Rezolute, Inc.

$416M

$4.32HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

SPRY

ARS Pharmaceuticals, Inc.

$427M

$4.30HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — RZLT vs SPRY

growth of $100 · dividends reinvested · last 6y

RZLT -78.4% (-22.5%/yr)SPRY -82.8% (-25.5%/yr)RZLT compounded faster over this window

RZLT SPRY

RZLT vs SPRY: by the numbers

•SPRY is the larger company ($427M vs $416M market cap).
•Both run net losses; RZLT's is the smaller (0.00% vs -184.24% net margin).

Metrics side by side

Valuation

Metric	RZLT	SPRY
P/S ratio	N/A	3.65
P/B ratio	4.13	34.09

Profitability

Metric	RZLT	SPRY
Gross margin	0.00%	73.89%
Operating margin	0.00%	-212.92%
Net margin	0.00%	-184.24%
ROE	-77.06%	-1721.80%
ROIC	-81.80%	-114.65%

Growth (annualized)

Metric	RZLT	SPRY
Revenue CAGR (5Y)	N/A	36.43%
Total return CAGR (5Y)	-9.57%	-16.35%

Frequently asked

How have RZLT and SPRY total returns compared?: Over the past 5 years, RZLT delivered -9.57% and SPRY delivered -16.35% annualized total return. Past performance doesn't predict future results.

Go deeper

Full RZLT analysis Full SPRY analysis Interactive comparison tool

Dig into the metrics

Rezolute ROE ARS Pharmaceuticals ROE Rezolute operating margin ARS Pharmaceuticals operating margin Rezolute revenue growth ARS Pharmaceuticals revenue growth Rezolute free cash flow ARS Pharmaceuticals free cash flow

Rezolute & ARS Pharmaceuticals appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.